Gain critical insights with confident MRD testing
Haystack MRD is a tumor-informed test, personalized for each patient. A test panel targeting up to 50 variants is developed to detect ctDNA in a blood sample. The test can then be performed whenever needed to monitor treatment response and detect residual or recurrent disease throughout the patient’s care journey.
-
Exceptional accuracy
-
Tumor-informed
-
Personalized
-
Track 50 variants
-
Baseline and Monitoring
Purpose-built
Enhanced performance for confidence in your MRD results
Our advanced tumor-informed minimal residual disease (MRD) test detects circulating tumor DNA (ctDNA) in blood using proprietary technology that double-checks each variant to eliminate sequencing noise. This ensures that whether ctDNA is detected or not, you can trust the results to help you more fully understand your patient’s disease status, delivering the confidence needed when answering patients’ most pressing questions.
This graphic is a theoretical representation only
High precision
Looking deeper to give you clearer answers
Designed to give you the best chance of getting the right answer the first time, Haystack MRD’s ultradeep sequencing reads each molecule up to 1 million times, delivering confident results to help guide critical treatment decisions.
Confidence to see more
Confidence that what you see is real
High-precision
Confidence in your MRD results from a test driven by technical and clinical rigor
With ctDNA detection technology backed by 2 NEJM-published studies—one using an earlier version and one using our current technology—Haystack MRD demonstrates both clinical impact and credibility.
Mature 5 year data The DYNAMIC TRIAL
Using an earlier generation of Haystack technology, the DYNAMIC trial became the first interventional study to show that ctDNA can guide adjuvant therapy decisions, with results validated after 5 years of follow-up.
Immunotherapy treatment response
1. Data on file. Haystack Oncology; 2024-2025.
2. Prathapam R, Champion K, Blakely K, et al. J Mol Diagn. 2024;26(11):S100; doi:10.1016/S1525-1578(24)00232-0
3. Cercek A, Foote MB, Rousseau B, et al. N Engl J Med. 2025;392(23):2297-2308. doi:10.1056/NEJMoa2404512
4. Tie J, Wang Y, Lo S, Gibbs, P. Nat Med. 2025;31(5):1509-1518